Gilead and Galapagos' much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage failure in idiopathic pulmonary fibrosis (IPF).
Boehringer Ingelheim and South Korea’s Bridge Biotherapeutics have decided to axe their collaboration over a potential new drug for idiopathic pulmonary fibrosis (IPF), BBT-877.
Privately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs including a potential inhaled idiopathic pulmonary fibrosis (IPF) m
Roche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for the deadly lung-scarring disease idiopathic pulmonary fibrosis (IPF) in a deal wort
AstraZeneca has become the latest big pharma to jump on the artificial intelligence R&D bandwagon, penning a deal with the UK’s BenevolentAI to find new kidney and lung drugs.<
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.